Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Use Surveillance for Cabometyx Tablets in Renal Cell Carcinoma
jRCT2031210003Completed
- Sponsor
- Takeda
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Takeda. Primary endpoints: Number of participants with adverse events and serious adverse events, Number of participants with Grade 3 or higher adverse events and 10 more. Started Mar 2021; status: completed.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2031210003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210003.